Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
LFW Photonics Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
COMPASS Pathways Plc - American Depository Shares
(NQ:
CMPS
)
9.460
+2.800 (+42.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about COMPASS Pathways Plc - American Depository Shares
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Small-Cap Medical Stocks: ATAI, CMPS, NDRA, PBM in Focus as U.S. Policy Accelerates Psychedelic Research
Today 16:39 EDT
Via
AB Newswire
This 4/20, Wall Street Is Betting on More Than Marijuana
↗
Today 15:05 EDT
Via
MarketBeat
Top movers analysis one hour before the close of the markets on 2026-04-20: top gainers and losers in today's session.
↗
Today 15:00 EDT
Via
Chartmill
This Psychedelic Biotech Stock Is Soaring After Trump Executive Order
↗
Today 13:24 EDT
COMPASS Pathways PLC (NASDAQ:CMPS) shares are soaring on Monday after President Donald Trump issued an executive order directing federal health agencies to speed up the review process for...
Via
Benzinga
Topics
Government
What's going on in today's session
↗
Today 12:30 EDT
Via
Chartmill
Why Compass Pathways Stock Rocketed 40% Today
↗
Today 12:22 EDT
Compass Pathways may be the first to benefit from an accelerated approval process.
Via
The Motley Fool
Topics
Government
Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar
↗
Today 11:27 EDT
Trump is easing approval for psychedelic treatments for mental disorders.
Via
The Motley Fool
Topics
Government
These stocks are gapping in today's session
↗
Today 10:30 EDT
Via
Chartmill
Top movers in Monday's pre-market session
↗
Today 8:30 EDT
Via
Chartmill
Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026
Today 6:30 EDT
From
Compass Pathfinder Limited
Via
Business Wire
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments
April 18, 2026
From
Compass Pathfinder Limited
Via
Business Wire
The Psychedelic Revolution in Mental Healthcare
↗
April 17, 2026
Founders of the Integrative Psychiatry Institute, Dr. Will Van Derveer and Keith Kurlander, discuss their new book, Psychedelic Therapy: A Revolutionary Approach to Restoring Mental Health and...
Via
The Motley Fool
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 07, 2026
From
Compass Pathfinder Limited
Via
Business Wire
The 15-Minute Breakthrough: A Deep Dive into GH Research (GHRS) and the Future of Rapid-Acting Psychedelics
March 26, 2026
Today’s Date: March 26, 2026 Introduction As the global mental health crisis reaches unprecedented levels, the pharmaceutical industry has been forced to look beyond traditional SSRIs toward more...
Via
Finterra
Topics
Cannabis
Initial Public Offering
Intellectual Property
Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights
March 24, 2026
From
Compass Pathfinder Limited
Via
Business Wire
Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026
March 12, 2026
From
Compass Pathfinder Limited
Via
Business Wire
Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants
February 26, 2026
From
Compass Pathfinder Limited
Via
Business Wire
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
February 24, 2026
EQNX::TICKER_START (NASDAQ:HELP),(CBOE:HELP),(NYSE:TAK),(NASDAQ:CMPS),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026
February 24, 2026
From
Compass Pathfinder Limited
Via
Business Wire
Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise
↗
February 20, 2026
Via
MarketBeat
Nasdaq, S&P 500 Futures Edge Higher, Trump Speech In Focus: Why WMT, META, IBRX, MSFT, EBAY Are On Traders' Radar Today
↗
February 19, 2026
Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral.
Via
Stocktwits
Topics
ETFs
Economy
Government
Compass Pathways Announces Pricing of $150 Million Public Offering
February 18, 2026
From
Compass Pathfinder Limited
Via
Business Wire
CMPS Stock Slumps Premarket As $150M Offering Cuts Into Psychedelic Trial Buzz
↗
February 18, 2026
The company CMPS is planning to seek FDA guidance on a rolling review and target a New Drug Application submission in the fourth quarter.
Via
Stocktwits
Compass Pathways Launches Proposed $150.0 Million Public Offering
February 17, 2026
From
Compass Pathfinder Limited
Via
Business Wire
Let's have a look at the top gainers and losers in the middle of the day of today's session.
↗
February 17, 2026
Via
Chartmill
Why Did Compass Pathways Stock Rocket Higher Today?
↗
February 17, 2026
Compass Pathways hopes to submit an NDA in Q4 leading up to potential approval.
Via
The Motley Fool
Tuesday's session: gap up and gap down stocks
↗
February 17, 2026
Via
Chartmill
Tuesday's pre-market session: top gainers and losers
↗
February 17, 2026
Via
Chartmill
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
February 17, 2026
From
Compass Pathfinder Limited
Via
Business Wire
CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial
↗
February 17, 2026
COMPASS Pathways is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.
Via
Stocktwits
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
